Carterra joins TetraScience Network to boost antibody services  

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates. 

The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers.  

Carterra will connect its LSA high-throughput surface plasmon resonance (SPR) platform and software to the Tetra Data Platform – enabling data from its LSA services to be used in advanced analytics and to help better inform antibody design and characterisation.  

Carterra’s LSA platform can screen and analyse antibodies faster than conventional approaches and was used by Eli Lilly when developing its Covid-19 therapeutic Bamlanivimab.  

Official comments  

“TPN is thrilled to welcome Carterra to the TPN, whose LSA instrument and software platform are creating a new standard in antibody discovery,” said Alan Millar, Vice President, TPN. “By connecting their world-leading solution with the Tetra Data Platform (TDP), together we can help customers accelerate scientific workflows and apply advanced analytics such as AI/ML to antibody design and characterisation.” 

“We are delighted to partner with TetraScience to create additional value for our customers,” said Tim Germann, Chief Commercial Officer, Carterra. “With diverse and global users of our platform, we need to continue to provide an array of tools for researchers to make better decisions sooner in the drug discovery process and this alliance with TetraScience will help us accomplish that.” 

“Biopharma R&D needs to unify and harmonise experimental data in the cloud in order to fully capitalize on the power of AI and data science,” said Patrick Grady, CEO of TetraScience. “In turn, AI and data science will uncover insights that will accelerate discovery and development of therapeutics that extend and enhance human life. Industry participants of all kinds – global pharmas, biotech startups, informatics providers, CROs, biopharma app companies, and more – recognise that this movement to the R&D Data Cloud must be driven by vendor-neutral and open partnerships that are deeply data-centric.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free